On Monday, Evotec stock experienced a shift in market sentiment as Jefferies adjusted its stance on the biotechnology company’s stock. Previously rated as a Buy, Evotec (NASDAQ:EVO) has now been downgraded to Hold. The firm also revised its price target for the shares, reducing it significantly to $3.80 from the earlier $8.70.
The revision by Jefferies comes amid expectations that Evotec’s strategic overhaul may encounter delays and that the market’s recovery could be protracted. The firm pointed to a current lack of clear indicators that could lead investors to ascribe substantial value to Evotec’s partnerships and assets in the near term. This uncertain business outlook, especially beyond 2025, along with the risk of further postponements to the company’s strategy update, might exacerbate investor concerns.
The analyst from Jefferies highlighted that while the potential for…
